Pharmacotherapy for Oesophagogastric Cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-12

AUTHORS

Christopher Jackson, Naureen Starling, Yu Jo Chua, David Cunningham

ABSTRACT

Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. Despite improvements in surgical and peri-operative supportive care, 3-year overall survival with surgery alone for resectable disease is still poor. Outcomes in localised oesophageal cancer are improved with pre-operative chemotherapy, and in gastric cancer with peri-operative treatment or post-operative chemoradiotherapy. Oesophageal squamous cell carcinoma can be treated with definitive chemoradiotherapy as an alternative to surgery. While survival in patients presenting with metastatic disease is improved with the addition of systemic chemotherapy, median survival remains <1 year. Patients who are otherwise fit can be offered chemotherapy and this is superior to best supportive care. Regimens including a platinum and an anthracycline agent are favoured by the results of randomised trials. No standard second-line therapy has emerged. New research into taxanes has shown promising anti-cancer activity, and novel areas of investigation include incorporation of agents targeting vascular endothelial growth factor or epidermal growth factor receptor into standard regimens. This review focuses on the clinical trial evidence that dictates the optimal management of localised and advanced oesophagogastric cancer, focusing on pharmacotherapy. We examine areas of current research and highlight future therapeutic directions. More... »

PAGES

2539-2556

References to SciGraph publications

  • 2003-04. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer in GASTRIC CANCER
  • 2004-01. Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study in INVESTIGATIONAL NEW DRUGS
  • 1995-03. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer in BRITISH JOURNAL OF CANCER
  • 1999-03. Comparison of Outcomes following Transhiatal or Ivor Lewis Esophagectomy for Esophageal Carcinoma in WORLD JOURNAL OF SURGERY
  • 1996-09. Cisplatin and etoposide in oesophageal cancer: a phase II study in BRITISH JOURNAL OF CANCER
  • 2003-02-01. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma in INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
  • 1998-08. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer in BRITISH JOURNAL OF CANCER
  • 2006-01-18. Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report in ANNALS OF SURGICAL ONCOLOGY
  • 2006-02. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer in GASTRIC CANCER
  • 1987-08. Adjuvant chemotherapy in gastric cancer in WORLD JOURNAL OF SURGERY
  • 2002-12. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia in JOURNAL OF GASTROINTESTINAL CANCER
  • 2005-05. Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer in GASTRIC CANCER
  • 2005-06-07. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial in BRITISH JOURNAL OF CANCER
  • 1990-08. Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach in INVESTIGATIONAL NEW DRUGS
  • 2002-02. Phase II Trial of Docetaxel Chemotherapy in Patients with Incurable Adenocarcinoma of the Esophagus in INVESTIGATIONAL NEW DRUGS
  • 2006-11-28. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer in BRITISH JOURNAL OF CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00003495-200767170-00006

    DOI

    http://dx.doi.org/10.2165/00003495-200767170-00006

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1020681357

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/18034590


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chemotherapy, Adjuvant", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Esophageal Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Stomach Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jackson", 
            "givenName": "Christopher", 
            "id": "sg:person.01305211717.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305211717.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Starling", 
            "givenName": "Naureen", 
            "id": "sg:person.01136565472.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chua", 
            "givenName": "Yu Jo", 
            "id": "sg:person.0644051644.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644051644.68"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cunningham", 
            "givenName": "David", 
            "id": "sg:person.01320161130.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1385/ijgc:32:2-3:115", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025786621", 
              "https://doi.org/10.1385/ijgc:32:2-3:115"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1998.524", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035200185", 
              "https://doi.org/10.1038/bjc.1998.524"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10120-003-0222-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013405635", 
              "https://doi.org/10.1007/s10120-003-0222-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01655812", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030258082", 
              "https://doi.org/10.1007/bf01655812"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00171847", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000917419", 
              "https://doi.org/10.1007/bf00171847"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1014476602804", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010318176", 
              "https://doi.org/10.1023/a:1014476602804"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/pl00013184", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036840454", 
              "https://doi.org/10.1007/pl00013184"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10120-004-0313-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052387774", 
              "https://doi.org/10.1007/s10120-004-0313-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00384-002-0464-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1075293195", 
              "https://doi.org/10.1007/s00384-002-0464-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6603497", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039743480", 
              "https://doi.org/10.1038/sj.bjc.6603497"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1995.114", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030614602", 
              "https://doi.org/10.1038/bjc.1995.114"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/aso.2006.01.001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034125184", 
              "https://doi.org/10.1245/aso.2006.01.001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6602645", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042693951", 
              "https://doi.org/10.1038/sj.bjc.6602645"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/b:drug.0000006179.20974.af", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039494468", 
              "https://doi.org/10.1023/b:drug.0000006179.20974.af"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1996.469", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037634793", 
              "https://doi.org/10.1038/bjc.1996.469"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10120-005-0351-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024546340", 
              "https://doi.org/10.1007/s10120-005-0351-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2007-12", 
        "datePublishedReg": "2007-12-01", 
        "description": "Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. Despite improvements in surgical and peri-operative supportive care, 3-year overall survival with surgery alone for resectable disease is still poor. Outcomes in localised oesophageal cancer are improved with pre-operative chemotherapy, and in gastric cancer with peri-operative treatment or post-operative chemoradiotherapy. Oesophageal squamous cell carcinoma can be treated with definitive chemoradiotherapy as an alternative to surgery. While survival in patients presenting with metastatic disease is improved with the addition of systemic chemotherapy, median survival remains <1 year. Patients who are otherwise fit can be offered chemotherapy and this is superior to best supportive care. Regimens including a platinum and an anthracycline agent are favoured by the results of randomised trials. No standard second-line therapy has emerged. New research into taxanes has shown promising anti-cancer activity, and novel areas of investigation include incorporation of agents targeting vascular endothelial growth factor or epidermal growth factor receptor into standard regimens. This review focuses on the clinical trial evidence that dictates the optimal management of localised and advanced oesophagogastric cancer, focusing on pharmacotherapy. We examine areas of current research and highlight future therapeutic directions.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00003495-200767170-00006", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1084788", 
            "issn": [
              "0012-6667", 
              "1179-1950"
            ], 
            "name": "Drugs", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "17", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "67"
          }
        ], 
        "keywords": [
          "metastatic disease", 
          "supportive care", 
          "oesophagogastric cancer", 
          "oesophageal cancer", 
          "gastric cancer", 
          "standard second-line therapy", 
          "oesophageal squamous cell carcinoma", 
          "peri-operative treatment", 
          "post-operative chemoradiotherapy", 
          "advanced oesophagogastric cancer", 
          "best supportive care", 
          "second-line therapy", 
          "clinical trial evidence", 
          "important disease entity", 
          "pre-operative chemotherapy", 
          "squamous cell carcinoma", 
          "vascular endothelial growth factor", 
          "future therapeutic directions", 
          "endothelial growth factor", 
          "epidermal growth factor receptor", 
          "promising anti-cancer activity", 
          "junctional tumours", 
          "resectable disease", 
          "definitive chemoradiotherapy", 
          "growth factor receptor", 
          "standard regimens", 
          "systemic chemotherapy", 
          "anti-cancer activity", 
          "overall survival", 
          "median survival", 
          "trial evidence", 
          "cell carcinoma", 
          "common cancer", 
          "anthracycline agent", 
          "disease entity", 
          "therapeutic directions", 
          "optimal management", 
          "cancer", 
          "chemotherapy", 
          "patients", 
          "growth factor", 
          "factor receptor", 
          "disease", 
          "chemoradiotherapy", 
          "regimens", 
          "pharmacotherapy", 
          "surgery", 
          "survival", 
          "care", 
          "incorporation of agents", 
          "carcinoma", 
          "therapy", 
          "tumors", 
          "taxanes", 
          "agents", 
          "incidence", 
          "trials", 
          "novel area", 
          "receptors", 
          "outcomes", 
          "treatment", 
          "review", 
          "years", 
          "evidence", 
          "new research", 
          "management", 
          "factors", 
          "activity", 
          "entities", 
          "improvement", 
          "current research", 
          "area", 
          "UK", 
          "addition", 
          "research", 
          "alternative", 
          "investigation", 
          "results", 
          "incorporation", 
          "platinum", 
          "direction"
        ], 
        "name": "Pharmacotherapy for Oesophagogastric Cancer", 
        "pagination": "2539-2556", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1020681357"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00003495-200767170-00006"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "18034590"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00003495-200767170-00006", 
          "https://app.dimensions.ai/details/publication/pub.1020681357"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:34", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_442.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00003495-200767170-00006"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-200767170-00006'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-200767170-00006'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-200767170-00006'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-200767170-00006'


     

    This table displays all metadata directly associated to this object as RDF triples.

    271 TRIPLES      21 PREDICATES      134 URIs      109 LITERALS      17 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00003495-200767170-00006 schema:about N28869d1e0e254283bacb0a2b37b971e6
    2 N3543dd7b334e4613a6ea9492fe3fbb07
    3 N403838492e4c4a3f9a0f5fe1342f22db
    4 N49dd2888474142b695d0e0aeea42e601
    5 N733c79a870344872801dfe6c46c20262
    6 N73da2be943cd47f4805c0635592c2379
    7 N8ca1e9c6c55a404b83612a41e28021cf
    8 Nc76cb161987a43cf946c1bdc8bb6c28b
    9 Ncfae81ccbfae4b0c835ffb57f37b7458
    10 Nfa69d01fbeb7423bb45ef2229803abce
    11 anzsrc-for:11
    12 anzsrc-for:1103
    13 anzsrc-for:1112
    14 schema:author Nb5da2c31fc7048e6af60953f715e9bdf
    15 schema:citation sg:pub.10.1007/bf00171847
    16 sg:pub.10.1007/bf01655812
    17 sg:pub.10.1007/pl00013184
    18 sg:pub.10.1007/s00384-002-0464-x
    19 sg:pub.10.1007/s10120-003-0222-y
    20 sg:pub.10.1007/s10120-004-0313-4
    21 sg:pub.10.1007/s10120-005-0351-6
    22 sg:pub.10.1023/a:1014476602804
    23 sg:pub.10.1023/b:drug.0000006179.20974.af
    24 sg:pub.10.1038/bjc.1995.114
    25 sg:pub.10.1038/bjc.1996.469
    26 sg:pub.10.1038/bjc.1998.524
    27 sg:pub.10.1038/sj.bjc.6602645
    28 sg:pub.10.1038/sj.bjc.6603497
    29 sg:pub.10.1245/aso.2006.01.001
    30 sg:pub.10.1385/ijgc:32:2-3:115
    31 schema:datePublished 2007-12
    32 schema:datePublishedReg 2007-12-01
    33 schema:description Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. Despite improvements in surgical and peri-operative supportive care, 3-year overall survival with surgery alone for resectable disease is still poor. Outcomes in localised oesophageal cancer are improved with pre-operative chemotherapy, and in gastric cancer with peri-operative treatment or post-operative chemoradiotherapy. Oesophageal squamous cell carcinoma can be treated with definitive chemoradiotherapy as an alternative to surgery. While survival in patients presenting with metastatic disease is improved with the addition of systemic chemotherapy, median survival remains <1 year. Patients who are otherwise fit can be offered chemotherapy and this is superior to best supportive care. Regimens including a platinum and an anthracycline agent are favoured by the results of randomised trials. No standard second-line therapy has emerged. New research into taxanes has shown promising anti-cancer activity, and novel areas of investigation include incorporation of agents targeting vascular endothelial growth factor or epidermal growth factor receptor into standard regimens. This review focuses on the clinical trial evidence that dictates the optimal management of localised and advanced oesophagogastric cancer, focusing on pharmacotherapy. We examine areas of current research and highlight future therapeutic directions.
    34 schema:genre article
    35 schema:isAccessibleForFree false
    36 schema:isPartOf Nbbc54745500042e4b895cc573860cbb9
    37 Nc7b6ae9dc8f546d5a1049c6192defd1f
    38 sg:journal.1084788
    39 schema:keywords UK
    40 activity
    41 addition
    42 advanced oesophagogastric cancer
    43 agents
    44 alternative
    45 anthracycline agent
    46 anti-cancer activity
    47 area
    48 best supportive care
    49 cancer
    50 carcinoma
    51 care
    52 cell carcinoma
    53 chemoradiotherapy
    54 chemotherapy
    55 clinical trial evidence
    56 common cancer
    57 current research
    58 definitive chemoradiotherapy
    59 direction
    60 disease
    61 disease entity
    62 endothelial growth factor
    63 entities
    64 epidermal growth factor receptor
    65 evidence
    66 factor receptor
    67 factors
    68 future therapeutic directions
    69 gastric cancer
    70 growth factor
    71 growth factor receptor
    72 important disease entity
    73 improvement
    74 incidence
    75 incorporation
    76 incorporation of agents
    77 investigation
    78 junctional tumours
    79 management
    80 median survival
    81 metastatic disease
    82 new research
    83 novel area
    84 oesophageal cancer
    85 oesophageal squamous cell carcinoma
    86 oesophagogastric cancer
    87 optimal management
    88 outcomes
    89 overall survival
    90 patients
    91 peri-operative treatment
    92 pharmacotherapy
    93 platinum
    94 post-operative chemoradiotherapy
    95 pre-operative chemotherapy
    96 promising anti-cancer activity
    97 receptors
    98 regimens
    99 research
    100 resectable disease
    101 results
    102 review
    103 second-line therapy
    104 squamous cell carcinoma
    105 standard regimens
    106 standard second-line therapy
    107 supportive care
    108 surgery
    109 survival
    110 systemic chemotherapy
    111 taxanes
    112 therapeutic directions
    113 therapy
    114 treatment
    115 trial evidence
    116 trials
    117 tumors
    118 vascular endothelial growth factor
    119 years
    120 schema:name Pharmacotherapy for Oesophagogastric Cancer
    121 schema:pagination 2539-2556
    122 schema:productId N02583047a063477694ea4e0c65a052ff
    123 Na6de4499b1cd490e88732096510d5465
    124 Nd85b19c5ac95409dafe5c86a282cd6af
    125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020681357
    126 https://doi.org/10.2165/00003495-200767170-00006
    127 schema:sdDatePublished 2022-10-01T06:34
    128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    129 schema:sdPublisher N6a8ac904c67347f1a92719f7ac329eff
    130 schema:url https://doi.org/10.2165/00003495-200767170-00006
    131 sgo:license sg:explorer/license/
    132 sgo:sdDataset articles
    133 rdf:type schema:ScholarlyArticle
    134 N02583047a063477694ea4e0c65a052ff schema:name dimensions_id
    135 schema:value pub.1020681357
    136 rdf:type schema:PropertyValue
    137 N18e8cb895e264a05b04c8421a4359f5d rdf:first sg:person.0644051644.68
    138 rdf:rest N77d1ebd3b2274ca093f866f1efc00819
    139 N28869d1e0e254283bacb0a2b37b971e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Humans
    141 rdf:type schema:DefinedTerm
    142 N3543dd7b334e4613a6ea9492fe3fbb07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Stomach Neoplasms
    144 rdf:type schema:DefinedTerm
    145 N403838492e4c4a3f9a0f5fe1342f22db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Antineoplastic Combined Chemotherapy Protocols
    147 rdf:type schema:DefinedTerm
    148 N49dd2888474142b695d0e0aeea42e601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Survival Rate
    150 rdf:type schema:DefinedTerm
    151 N6a8ac904c67347f1a92719f7ac329eff schema:name Springer Nature - SN SciGraph project
    152 rdf:type schema:Organization
    153 N733c79a870344872801dfe6c46c20262 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Neoplasm Recurrence, Local
    155 rdf:type schema:DefinedTerm
    156 N73da2be943cd47f4805c0635592c2379 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Clinical Trials as Topic
    158 rdf:type schema:DefinedTerm
    159 N77d1ebd3b2274ca093f866f1efc00819 rdf:first sg:person.01320161130.16
    160 rdf:rest rdf:nil
    161 N8ca1e9c6c55a404b83612a41e28021cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Treatment Outcome
    163 rdf:type schema:DefinedTerm
    164 Na6de4499b1cd490e88732096510d5465 schema:name pubmed_id
    165 schema:value 18034590
    166 rdf:type schema:PropertyValue
    167 Nb5da2c31fc7048e6af60953f715e9bdf rdf:first sg:person.01305211717.47
    168 rdf:rest Nf6ab8a3c92f74417a8c2526e3f79f40b
    169 Nbbc54745500042e4b895cc573860cbb9 schema:volumeNumber 67
    170 rdf:type schema:PublicationVolume
    171 Nc76cb161987a43cf946c1bdc8bb6c28b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Esophageal Neoplasms
    173 rdf:type schema:DefinedTerm
    174 Nc7b6ae9dc8f546d5a1049c6192defd1f schema:issueNumber 17
    175 rdf:type schema:PublicationIssue
    176 Ncfae81ccbfae4b0c835ffb57f37b7458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Chemotherapy, Adjuvant
    178 rdf:type schema:DefinedTerm
    179 Nd85b19c5ac95409dafe5c86a282cd6af schema:name doi
    180 schema:value 10.2165/00003495-200767170-00006
    181 rdf:type schema:PropertyValue
    182 Nf6ab8a3c92f74417a8c2526e3f79f40b rdf:first sg:person.01136565472.17
    183 rdf:rest N18e8cb895e264a05b04c8421a4359f5d
    184 Nfa69d01fbeb7423bb45ef2229803abce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Disease Progression
    186 rdf:type schema:DefinedTerm
    187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    188 schema:name Medical and Health Sciences
    189 rdf:type schema:DefinedTerm
    190 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    191 schema:name Clinical Sciences
    192 rdf:type schema:DefinedTerm
    193 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    194 schema:name Oncology and Carcinogenesis
    195 rdf:type schema:DefinedTerm
    196 sg:journal.1084788 schema:issn 0012-6667
    197 1179-1950
    198 schema:name Drugs
    199 schema:publisher Springer Nature
    200 rdf:type schema:Periodical
    201 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.424926.f
    202 schema:familyName Starling
    203 schema:givenName Naureen
    204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
    205 rdf:type schema:Person
    206 sg:person.01305211717.47 schema:affiliation grid-institutes:grid.424926.f
    207 schema:familyName Jackson
    208 schema:givenName Christopher
    209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305211717.47
    210 rdf:type schema:Person
    211 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.424926.f
    212 schema:familyName Cunningham
    213 schema:givenName David
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
    215 rdf:type schema:Person
    216 sg:person.0644051644.68 schema:affiliation grid-institutes:grid.424926.f
    217 schema:familyName Chua
    218 schema:givenName Yu Jo
    219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644051644.68
    220 rdf:type schema:Person
    221 sg:pub.10.1007/bf00171847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000917419
    222 https://doi.org/10.1007/bf00171847
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1007/bf01655812 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030258082
    225 https://doi.org/10.1007/bf01655812
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1007/pl00013184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840454
    228 https://doi.org/10.1007/pl00013184
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1007/s00384-002-0464-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1075293195
    231 https://doi.org/10.1007/s00384-002-0464-x
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1007/s10120-003-0222-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1013405635
    234 https://doi.org/10.1007/s10120-003-0222-y
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1007/s10120-004-0313-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052387774
    237 https://doi.org/10.1007/s10120-004-0313-4
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1007/s10120-005-0351-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024546340
    240 https://doi.org/10.1007/s10120-005-0351-6
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1023/a:1014476602804 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010318176
    243 https://doi.org/10.1023/a:1014476602804
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1023/b:drug.0000006179.20974.af schema:sameAs https://app.dimensions.ai/details/publication/pub.1039494468
    246 https://doi.org/10.1023/b:drug.0000006179.20974.af
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1038/bjc.1995.114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030614602
    249 https://doi.org/10.1038/bjc.1995.114
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1038/bjc.1996.469 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037634793
    252 https://doi.org/10.1038/bjc.1996.469
    253 rdf:type schema:CreativeWork
    254 sg:pub.10.1038/bjc.1998.524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035200185
    255 https://doi.org/10.1038/bjc.1998.524
    256 rdf:type schema:CreativeWork
    257 sg:pub.10.1038/sj.bjc.6602645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042693951
    258 https://doi.org/10.1038/sj.bjc.6602645
    259 rdf:type schema:CreativeWork
    260 sg:pub.10.1038/sj.bjc.6603497 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039743480
    261 https://doi.org/10.1038/sj.bjc.6603497
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1245/aso.2006.01.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034125184
    264 https://doi.org/10.1245/aso.2006.01.001
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1385/ijgc:32:2-3:115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025786621
    267 https://doi.org/10.1385/ijgc:32:2-3:115
    268 rdf:type schema:CreativeWork
    269 grid-institutes:grid.424926.f schema:alternateName Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom
    270 schema:name Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, United Kingdom
    271 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...